1.
Farnsworth A: Screening for the prevention of cervical cancer in the era of human papillomavirus vaccination: an Australian perspective. Acta Cytol 2011;55:307–312.
2.
Mayrand MH, Duarte-Franco E, Rodrigues I, et al: Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007;357:1579–1588.
3.
Mayrand MH, Duarte-Franco E, Coutlee F, et al: Randomised controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian Cervical Cancer Screening Trial (CCCaST). Int J Cancer 2006;119:614–623.
4.
Canfell K, Sitas F, Beral V: Cervical cancer in Australia and the United Kingdom: comparison of screening policy and uptake, and cancer incidence and mortality Med J Aust 2006;185:482–486.
5.
Khan MJ, Castle PE, Lorincz AT, et al: The elevated 10 year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 and 18 and the possible utility of type specific HPV testing in clinical practice. J Natl Cancer Inst 2005;97:1072–1079.
6.
Dillner J, Rebolj M, Birembaut P, et al: Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008;337:a1754.
7.
Australian Institute of Health and Welfare: Cervical Screening in Australia 2008–2009. Cancer series no. 61. Cat. no. CAN 57. Canberra, AIHW, 2011. http://www.aihw.gov.au/publication-detail/?id=10737420251.
8.
Screening to prevent cervical cancer: guidelines for the management of asymptomatic women with screen-detected abnormalities. 2005. http://www.nhmrc.gov.au/guidelines/publications/wh39.
9.
Human papillomavirus testing as a triage strategy for women with cytologic evidence of low grade squamous intraepithelial lesions: baseline data from a randomised trial – the Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group. J Natl Cancer Inst 2000;92:397–402.
10.
Solomon D, Schiffman M, Tarone R, ALTS Study Group: Comparison of three management strategies for patients with atypical squamous cell of undetermined significance: baseline results from a randomised trial. J Natl Cancer Inst 2001;93:293–299.
11.
Castle PE, Stoler MH, Wright C, Sharma A, Wright TL, Behrens CM: Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol 2011;12:880–900.
12.
Franco EL, Cuzick J: Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine 2008;26(suppl 1):A16–A23.
13.
Schiffman M: Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing. Cancer 2007:111:145–153.
14.
Castle PE, Schiffman M, Wheeler CM, Wentzensen N, Gravitt PE: Human papillomavirus genotypes in cervical intraepithelial neoplasia grade 3. Cancer Epidemiol Biomarkers Prev 2010;19:1675–1681.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the...
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.